News | News By Subject | News by Disease News By Date | Search News

Crohn's disease News Articles

Get Our FREE
Industry eNewsletter
email:    
Top Breaking News
Gilead (GILD) Looking Even Weaker on the R&D Front as It Racks Up Some More Clinical Failures in Q3 Report     11/2/2016
What You May Have Missed: Critics Point to Problems With Celgene (CELG)’s Crohn’s Drug Trial Design     10/20/2016
TiGenix Lands $400 Million+ Crohn's Disease Deal with Pharma Giant Takeda (TKPYY)     7/6/2016
10 Massachusetts Biotechs that Grew Their Headcount by at Least 40% in 2015     3/24/2016
AbbVie (ABBV) Coughs Up $595 Million+ for Boehringer Ingelheim's Psoriasis and Crohn’s Drugs     3/8/2016
Galapagos (GLPG.BR) Crohn’s Trial Data Might Make it An Attractive M&A Target for Amgen (AMGN)     12/9/2015
Top 10 Best-Selling Biotech Drugs     10/2/2015
TiGenix's Cx601 Meets Primary Endpoint in Phase III Study     8/31/2015
AstraZeneca PLC (AZN) Offloads Crohn's Disease Drug for $215 Million     7/10/2015
AmerisourceBergen Corporation (ABC) the “Pony to Ride” for Biosimilar Opportunities, Says UBS     3/16/2015
J.P. Morgan: Celgene (CELG) to Fast-Track Crohn's Drug, Provides Estimates Up to 2020     1/13/2015
Analyst: Current Crop of Biotech IPOs a Mixed Bag of Low Market Caps, Little Data     12/3/2014
Best Value In Biotech? Actavis (ACT), Says UBS     11/17/2014
Celgene (CELG)’s New Crohn’s Disease Drug Impressing Analysts     10/21/2014
Celgene Corporation (CELG) Antes Up $710 Million Upfront For Phase 3-Ready Crohn's Disease Drug     4/24/2014

News from Around the Web
Mothers Can Pass Traits To Offspring Through Bacteria's DNA, Washington University in St. Louis Study     2/23/2015
Could Gut Bacteria That Help Us Digest Beer & Bread Fight Disease, Too? University of Michigan Medical School Study     1/8/2015
Genetically Engineered Bacteria Could Help in Crohn's and Colitis, Centre de Physiopathologie de Toulouse-Purpan Study     11/2/2012
Potential New Drug Therapy for Crohn's Disease, University of California, San Diego (UCSD) Study     10/18/2012
Discovery Finds Cancer Drugs Offer New Hope for Crohn's Disease and Sarcoidosis, Case Western Reserve University Study     12/1/2010
Adding Immunomodulating Agents and Corticosteroids to Adalimumab Increases Risks of Infection for Patients With Crohn's Disease, Mayo Clinic Study Presented at American College of Gastroenterology     10/22/2010
American College of Gastroenterology: Acute IBD Flares Respond to Infliximab, University of Pittsburgh Study     10/20/2010
American College of Gastroenterology: Upfront Biologics Improve Crohn's Outcomes, State University of New York at Buffalo Study     10/19/2010
Broccoli, Plantains May Stop Crohn's Disease Relapse, University of Liverpool and Collaborators Study     8/26/2010
Prebiotics Won't Relieve Crohn's, According to Research Presented at Digestive Disease Week     5/7/2010
Better Treatment Found for Crohn's Disease, Mayo Clinic Study     4/15/2010
Genetic Variants Associated With a Risk of Crohn's Disease, University of Copenhagen Study     4/7/2010
Gene Discovery Gives Clues to Crohn's Disease, Colitis, University College London Study     11/5/2009
UK Scientists Say They've Found A Cure For Crohn's, University of Nottingham Study     6/26/2009
Probiotic May Help Treat Crohn's Disease, Institut National de Recherche Agronomique Study     10/21/2008

Press Releases
AbbVie (ABBV) Receives Orphan Drug Designation For Investigational IL-23 Inhibitor Risankizumab From The U.S. FDA For The Treatment Of Pediatric Patients With Crohn's Disease     12/1/2016
Takeda (TKPYY) Release: New Treatment For Ulcerative Colitis And Crohn’s Disease Launched In UAE     11/29/2016
Janssen Pharmaceutical Companies Release: Phase 3 Study Results Supporting U.S. FDA And European Commission (EC) Approvals Of STELARA In The Treatment Of Moderately To Severely Active Crohn's Disease Published In The New England Journal of Medicine     11/17/2016
Janssen-Cilag International NV (JNJ) Release: European Commission (EC) Approves STELARA (Ustekinumab) For Treatment Of Adults With Moderately To Severely Active Crohn’s Disease     11/11/2016
SetPoint Presents Positive Clinical Results In Crohn’s Disease     10/19/2016
Celgene (CELG) Release: Oral GED-0301 Phase 1b Results Show Clinical Remission And Endoscopic Response At Week 12 In Patients With Active Crohn's Disease     10/17/2016
Celgene (CELG) Shows Off Crohn's Disease Data in Small Mid-Stage Study     10/17/2016
RedHill Biopharma (RDHL) Provides Progress Update On RHB-104 Phase III Crohn’s Disease Program And Introduces Option For Early Stop For Success In Q2/2017     10/6/2016
Takeda Pharmaceutical Co. Ltd. (TKPYY) Release: Additional Interim Data Supporting Long-Term Use Of Vedolizumab In Patients With Ulcerative Colitis And Crohn's Disease Published In Journal Of Crohn's And Colitis     9/29/2016
Janssen Biotech (JNJ) Release: FDA Approves STELARA (ustekinumab) For Treatment Of Adults With Moderately To Severely Active Crohn's Disease     9/26/2016
Galapagos (GLPG.BR) Release: Endoscopic Improvements With Filgotinib Are Consistent With Clinical Remission Rates In Patients With Crohn's Disease     9/26/2016
Janssen-Cilag International NV (JNJ) Receives CHMP Positive Opinion For STELARA (Ustekinumab) Recommending Approval For The Treatment Of Moderately To Severely Active Crohn’s Disease In The European Union     9/16/2016
Celgene (CELG) Touts Early Stage Crohn’s Disease Data     9/12/2016
Celgene (CELG) Announces Interim Topline Data From Trial Of Investigational Oral GED-0301 In Patients With Active Crohn’s Disease     9/12/2016
Takeda (TKPYY) And TiGenix Announce Publication In The Lancet Of 24-Week Results Of The Phase 3 ADMIRE-CD Trial Investigating Cx601 In The Treatment Of Complex Perianal Fistulas In Patients With Crohn's Disease     8/2/2016

//-->